EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma

Makoto Yoshimitsu iD, Takashi Tanaka, Nobuaki Nakano, Koji Kato iD, Hiroyuki Muranushi, Masahito Tokunaga iD, Ayumu Ito, Jun Ishikawa, Tetsuya Eto, Satoko Morishima iD, Toshiro Kawakita, Hidehiro Itonaga iD und 12 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.19835 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Makoto Yoshimitsu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Hauptthemen laut MEDLINE: Cyclophosphamide, Leukemia-Lymphoma, Adult T-Cell, Transplantation, Haploidentical, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo‐HCT) platforms in patients with adult T‐cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)‐haploidentical‐related donors using post‐transplant cyclophosphamide (PTCY), HLA‐matched related donors (MRD), HLA‐matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo‐HCT between 2016 and 2021 were included. Outcomes analysed were overall survival (OS), relapse and non‐relapse mortality (NRM). Seven hundred patients were included (PTCY, n = 121; MRD, n = 91; MUD, n = 160; CBT, n = 328). With a median follow‐up of 794 days for survivors, 2‐year OS was 48.1% (PTCY), 48.8% (MRD), 48.4% (MUD) and 34.6% (CBT); the respective 2‐year cumulative incidence of relapse was 37.1%, 47.5%, 33.9% and 45.1% and that of NRM was 24.2%, 19.8%, 24.7% and 27.3%. PTCY was associated with delayed platelet engraftment relative to MRD and MUD. There was no increase in the incidence of severe acute or chronic graft‐versus‐host disease. In the PTCY group, poor performance status was a significant predictor of inferior OS, and infused CD34+ cell numbers of less than 5 × 10 6 /kg were associated with delayed neutrophil and platelet engraftment. These results suggest that allo‐HCT with PTCY is a safe and effective platform for patients with adult T‐cell leukaemia/lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideLeukemia-Lymphoma, Adult T-CellTransplantation, HaploidenticalHematopoietic Stem Cell TransplantationHumansAdultFemaleMaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeYoung AdultGraft vs Host DiseaseAdolescent

Stichwörter der Autor:innen

adult T‐cell leukaemia/lymphomagraft‐versus‐host diseasehaploidentical haematopoietic stem cell transplantationpost‐transplant cyclophosphamideprophylaxis

Substanzen

Cyclophosphamide

Autor:innen und Institutionen

  • Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Department of Hematology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.

ORCID-Profile: Makoto Yoshimitsu, Koji Kato, Masahito Tokunaga, Satoko Morishima, Hidehiro Itonaga, Naoyuki Uchida, Shuichi Ota, Yoshinobu Kanda, Yoshiko Atsuta, Shigeo Fuji

Förderung

  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Yoshimitsu, M., Tanaka, T., Nakano, N., Kato, K., Muranushi, H., Tokunaga, M., Ito, A., Ishikawa, J., Eto, T., Morishima, S., Kawakita, T., Itonaga, H., Uchida, N., Tanaka, M., Akizuki, K., Ishitsuka, K., Ohigashi, H., Ota, S., Ando, T., …, & ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy (2025). Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.19835

Vancouver

Yoshimitsu M, Tanaka T, Nakano N, Kato K, Muranushi H, Tokunaga M, et al. Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma. British Journal of Haematology. 2025. doi:10.1111/bjh.19835

BibTeX
@article{Yoshimitsu2025,
  author = {Yoshimitsu, Makoto and Tanaka, Takashi and Nakano, Nobuaki and Kato, Koji and Muranushi, Hiroyuki and Tokunaga, Masahito and Ito, Ayumu and Ishikawa, Jun and Eto, Tetsuya and Morishima, Satoko and Kawakita, Toshiro and Itonaga, Hidehiro and Uchida, Naoyuki and Tanaka, Masatsugu and Akizuki, Keiichi and Ishitsuka, Kenji and Ohigashi, Hiroyuki and Ota, Shuichi and Ando, Toshihiko and Kanda, Yoshinobu and Fukuda, Takahiro and Atsuta, Yoshiko and Fuji, Shigeo and ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy, ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy},
  title = {Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.19835}
}
Kostenlos starten →